Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?

참고문헌 (12)

1. Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
2. Wilson PW, "Systematic review for the 2018AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
3. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
4. 심두선, "Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol", 지질·동맥경화학회지, 8(2), pp.208~220 (2019), 한국지질동맥경화학회[DOI]
5. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
6. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
7. Rallidis LS, "Extreme-risk category: high prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg", dL, 2018, pp.275, 262~264
8. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
9. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
10. Cho KH, "Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox)", Am J Cardiol, 106, pp.1061~1068 (2010)
11. McKinney JS, "Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31randomized controlled trials", Stroke, 43, pp.2149~2156 (2012)
12. 천경현, "Incidence, Predictors, and Clinical Outcomes of New-Onset Diabetes Mellitus after Percutaneous Coronary Intervention with Drug-Eluting Stent", Journal of Korean Medical Science, 32(10), pp.1603~1609 (2017), 대한의학회

관련 논문AI추천